ImmunoGen Message Board - Msg: 32465471

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Mohilner who wrote (5629)	12/17/2019 5:56:49 PM
From: Wildbiftek	Read Replies (1) of 5665

The FDA has finally given them a reasonable and relatively easy out for the technical failure that was FORWARD I which would have been successful had they adopted a slightly different statistical plan. They have enough assurances of due diligence in place with the additional confirmatory trial in MIRASOL and now in SORAYA. I think the market is underestimating the value of their lead agent which should address ~4-5,000 patients initially and move into earlier stages of therapy in combination. Their 3rd and 4th generation linker / toxins likely confer survival benefit due to their much better tolerability and should be ideal in a combination setting as well. Pt. resistant ovarian cancer continues to have substantial unmet need and the value of an approved MS (depending on what they charge, and I'm assuming $150k a year for a course of therapy) in the salvage setting could be around $3-4B market cap which translates to around $20-$25 a share.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next